Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)

Similar documents
Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists

Treatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG

Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center

IBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital

Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10

Doncaster & Bassetlaw Medicines Formulary

PEDIATRIC INFLAMMATORY BOWEL DISEASE

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012

September 12, 2015 Millie D. Long MD, MPH, FACG

Efficacy and Safety of Treatment for Pediatric IBD

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014

IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

Indications for use of Infliximab

Ali Keshavarzian MD Rush University Medical Center

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

Primary & Secondary Care Inflammatory Bowel Disease Pathway February 2018

DENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease

Efficacy and Safety of Treatment for Pediatric IBD

Mucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium

Inflectra Frequently Asked Questions

Crohn's Disease. The What, When, and Why of Treatment

Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων

Clinical guideline Published: 10 October 2012 nice.org.uk/guidance/cg152

Fistulizing Crohn s Disease: The Aggressive Approach

Management of the Hospitalized IBD Patient. Drew DuPont MD

IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD

Title: Author: Journal:

Moderately to severely active ulcerative colitis

Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?

Clinical Study Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis

Predicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium

Guideline Ulcerative colitis: management

Common Questions in Crohn s Disease Therapy. Case

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants

Implementation of disease and safety predictors during disease management in UC

P a g e 1. Inflammatory Bowel Disease Guidelines

The Best of IBD at UEGW (Crohn s)

National Institute for Health and Care Excellence

Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College

To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy

Pharmacotherapy of Inflammatory Bowel Disorder

Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010

Slide 1 Medications in inflammatory bowel disease a primer for health care providers. Slide 2. Slide 3 Theory of pathogenesis. IBD - epidemiology

Perianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic

Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease

This information explains the advice about Crohn's disease that is set out in NICE guideline CG152.

Perianal Fistula of Crohn s Disease

Improving outcome of Inflammatory Bowel Disease in children

Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children

Azathioprine for Induction and Maintenance of Remission in Crohn s Disease

Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis

Medical Management of Inflammatory Bowel Disease

IBD in teenagers Biological and Transition

Ulcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13

John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah

OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG

Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France

Diarrhoea for the Acute Physician

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD

Dr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)

Identifying and Managing Patients with IBD at Risk for Progressive Disease

INFLAMMATORY BOWEL DISEASE

Pharmacotherapy of Inflammatory Bowel Disorder

My Child Has Inflammatory Bowel Disease : Why? What now? What s next?

NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL

Patho Basic Chronic Inflammatory Bowel Diseases. Jürg Vosbeck Pathology

Endpoints for Stopping Treatment in UC

Medical Therapy for Pediatric IBD: Efficacy and Safety

-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency

Join the conversation at #GIFORUMCCFA

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

10/23/2014. Program Goals

How to manage your IBD patient: Tips for diagnosis and care

Ulcerative Colitis: State of the Art 2006

Crohn s Disease: A New Approach to an Old Problem

Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida

What is Crohn's disease?

Withdrawal of drug therapy in patients with quiescent Crohn s disease

SURGICAL MANAGEMENT OF ULCERATIVE COLITIS

Practical Risk Management Tools for Patients with IBD. Garth Swanson MD Rush University Medical Center

5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease

Algorithm for managing severe ulcerative colitis

IBD Biologicals and Novel therapeutic regimes. Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh

Surgical Management of IBD. Val Jefford Grand Rounds October 14, 2003

Treating Crohn s and Colitis in the ASC

Crohn's Disease. The What, When, and Why of Treatment

Achieving Success in Ulcerative Colitis: the Role of Infliximab

Selby Inflamm Bowel Dis. 2008:14:

Modern Management of Perianal Fistulas in Crohn s Disease (PFCD): Future Directions

The Road to Remission

ULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC

Crohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine

Prevention and Management of Postoperative Crohn s disease

Inflammatory Bowel Disease

Transcription:

CROHN S DISEASE

Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission: Absent or minimal endoscopic lesions response: clinical improvement within 2-3 weeks of corticosteroid therapy, or up to 12 weeks of anti-tnf therapy Relapse: Flare of symptoms associated with evidence of inflammation as determined by CRP, fecal calprotectin, MR or CT enterography, endoscopy or ultrasound and absence of viral/bacterial infection Steroid-resistant: Patients who have active disease despite prednisolone of up to 0.75 mg/kg/day over a period of 4 weeks Steroid-dependent: Patients who are either -Unable to reduce steroids below the equivalent of prednisolone 10 mg/day within 3 months of starting steroids without recurrent active disease, or -Who have a relapse within 3 months of stopping steroids

Treatment Algorithm for Crohn s Disease Provide patients with Crohn s Disease proper education and advice on smoking cessation, drug adherence and fertility Assess extent and severity using endoscopy ± MR or CT enterography Mild ileal/ ileocolonic Moderate ileal/ ileocolonic Severe/extensive luminal disease Fistulizing disease Severe perianal disease 2 5-ASA Steroid/budenoside taper over 6-8 weeks 12 Exclude/drain abscess Clinical remission Lack of response/ worsening symptoms Re-evaluate in 2-4 weeks Anti-TNF therapy +/- AZA/6MP/MTX Re-evaluate 8-12 weeks after initiation Continue + regular follow-up Stop + follow-up consider 5-ASA if colonic disease Re-evaluate in 3-6 months Recurrent symptoms, need new course of CS, relapse when tapering CS < 10mg (steroid-dependent) or within 3-6 months of stopping CS 1. Corticosteroids (CS) taper: From 40-60mg/d to 0mg/ day over 6-8 weeks by 5-10mg/wk. 2. consider surgery/gyn consult for perineal disease consider adding 5-ASA in colonic disease as chemoprevention. Steroids/budenoside taper + start AZA/6MP/ MTX Relapse or suboptimal response Loss of response Go to Algorithm A response Consider alternative emerging therapy surgery =Consider referral to a multidisciplinary IBD servic AZA: Azathioprine MTX: Methotrexate 6MP: 6-Mercaptopurine

ULCERATIVE COLITIS

Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Endoscopic remission: Absent or minimal endoscopic lesions Relapse: Flare of symptoms (blood in stool, tenesmus, diarrhea) with or without evidence of mucosal inflammation and in the absence of concomitant infection Steroid-resistant: Patients who have active disease despite prednisolone of up to 0.75 mg/kg/day over a period of 4 weeks Steroid-dependent: Patients who are either: -Unable to reduce steroids below the equivalent of prednisolone 10 mg/day within 3 months of starting steroids, without recurrent active disease, or -Who have a relapse within 3 months of stopping steroids

Treatment Algorithm for Ulcerative Colitis Patient diagnosed with Ulcerative Colitis Determine severity and extent Mild to moderate left distal colitis/ proctitis Mild to moderate extensive colitis Moderate to severe extensive colitis Severe to fulminant colitis

Mild to Moderate Distal Colitis Proctitis Proctosigmoiditis 5-ASA suppositories for 4 to 6 weeks Oral 5-ASA (induction dose) + 5-ASA enema for 4 to 6 weeks 5-ASA suppositories maintenance dose Add topical steroid and/or oral 5-ASA Oral +/- enema 5-ASA maintenance dose Oral steroid + 5-ASA Oral + topical 5-ASA maintenance dose Oral + topical 5- ASA maintenance dose (± Azathioprine) Anti-TNF alpha Oral steroid + oral 5-ASA + rectal ASA 5-ASA: 5-aminosalicylic acid Maintenance dose 5-ASA Steroid dose induction + Azathioprine + 5-ASA Azathioprine + 5-ASA Anti-TNF alpha

Mild to Moderate Extensive Colitis Oral + topical 5-ASA Oral 5-ASA maintenance dose Oral steroid + oral 5-ASA 5-ASA maintenance dose Relapse Add Azathioprine Check adherence/ reassess disease activity Oral steroid (taper dose) + Azathioprine 5-ASA: 5-aminosalicylic acid

Moderate to Severe Extensive Colitis Oral steroid + oral 5-ASA Azathioprine + 5-ASA maintenance dose Hospital admission, IV steroid Objective response after 3-5 days Oral steroids + Azathioprine + oral 5- ASA Azathioprine (if CsA ) or Anti-TNF alpha Consult surgery Cyclosporine or Anti-TNF alpha Surgery 5-ASA: 5-aminosalicylic acid CsA: Cyclosporine

Severe to Fulminant Ulcerative Colitis IV steroid + initiate DVT prophylaxis + consult surgery Objective response 3 rd day Oral steroid (taper dose) + Azathioprine Anti-TNF alpha or Cyclosporine (CsA) relapse Azathioprine + 5- ASA maintenance dose Recurrence or steroid-resistant or steroid-dependent Anti-TNF alpha + 5-ASA Anti-TNF alpha or Azathioprine (if CsA) Surgery 5-ASA: 5-aminosalicylic acid CsA: Cyclosporine DVT: Deep Venous Thrombosis

Algorithm A: Loss of Response to 1st Anti-TNF Agent Evaluate for inflammation and complications Inflammation complication Inflammation complication Inflammation complication Inflammation complication (eg. Abscess) Consider check ADA and trough level (TL) Symptomatic treatment Specific treatment for complication Stop biologic, surgical evaluation, completely drain abscess Low ADA Low TL High ADA Low TL Low ADA Adequate TL Increase dose Increase dose and/or and/or decrease decrease interval, add interval immunomodulator or switch to 2 nd anti-tnf Switch to 2 nd anti-tnf or switch to agent from a different class ADA: Anti-Drug Antibodies TL: Trough Level